PT  - JOURNAL ARTICLE
AU  - Denise N. Slenter
AU  - Irene M.G.M. Hemel
AU  - Chris T. Evelo
AU  - Jörgen Bierau
AU  - Egon L. Willighagen
AU  - Laura K.M. Steinbusch
TI  - A Systems Biology Workflow to Support the Diagnosis of Pyrimidine and Urea Cycle Disorders
AID  - 10.1101/2022.01.31.21265847
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.31.21265847
4099  - http://medrxiv.org/content/early/2022/02/04/2022.01.31.21265847.short
4100  - http://medrxiv.org/content/early/2022/02/04/2022.01.31.21265847.full
AB  - Background Pyrimidine (and purine) metabolism provides essential high-energy vehicles, universal throughout all life, which carry both activated metabolites that serve as fuel and building blocks for countless metabolic processes as well as the messenger molecules that steer these processes. Furthermore, these nitrogen-containing structures encode the alphabet needed to construct the genetic code. The pyrimidine pathway overlaps with the Urea Cycle through a common metabolite (carbamoyl phosphate), with the urea cycle being responsible for the production of several amino acids and removing ammonia. Various Inherited Metabolic Disorders (IMDs) disrupt these pathways, with considerably large phenotypic variation in affected patients, hindering diagnosis. Moreover, the biomarkers for these disorders overlap substantially between the IMDs and their underlying biological pathways, interfering with identifying the deficient protein. We developed a framework that allows us to combine clinical and theoretical biomarkers with pathway models through network approaches and semantic web technologies to support the diagnosis of pyrimidine and urea cycle IMDs.Methods We integrated literature and expert knowledge into machine-readable pathway models for pyrimidine and urea cycle disorders, including disease information and relevant downstream biomarkers. The theoretical change for each biomarker per disease was compiled based on a manual database search. The top three pathways of interest were retrieved through semantic web technologies, by selecting pathways that covered most unique markers as well as showing overlap with the theoretical marker data. These pathways and the corresponding clinical data were visualized through network analysis. Two expert laboratory scientists evaluated our approach by diagnosing a cohort of sixteen previously diagnosed patients with various pyrimidine and urea cycle disorders, based on a visualization of theoretical biomarker overlap with patient data, as well as top three pathways displaying the relationships between the individual biomarkers.Results The number of relevant biomarkers for each patient varies greatly (five to 48), and likewise the pathways covering most unique biomarkers differ for equivalent disorders. The two experts reached similar conclusions regarding the diagnosis of nine patient samples without knowledge about clinical symptoms or sex. For the remaining seven cases, four interpretations pointed in the direction of a subset of disorders, which could be prioritized for further investigation. Three cases were found to be undiagnosable with the data available.Conclusion The presented workflow supports the diagnosis of several IMDs of pyrimidine and urea cycle pathways, by directly linking biological pathway knowledge and theoretical biomarker data to clinical cases. This workflow is adaptable to analyze different types of IMDs, difficult patient cases and functional assays in the future. Furthermore, the pathway models can be used as a basis to perform various other types of (omics) data analysis, e.g. transcriptomics, metabolomics, fluxomics.Data Availability The data used in this study have been deposited at https://github.com/BiGCAT-UM/IMD-PUPY.Highlights- Machine readable pathway models suitable for purine, pyrimidine, and urea cycle omics data analysis- Visualizing clinically validated biomarkers with pathway knowledge and theoretical biomarker data- Utilizing semantic web technology and network approaches to precisely represent the biochemistry underlying pyrimidine and urea cycle disorders- Opens up the possibility to visualize the interactions between metabolic pathways, which can be used in the diagnostic workflow- Approach is extendable to other inherited metabolic disordersCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:To whom it may concern: the Medical Research Involving Human Subjects Act (WMO) did not apply to the above-mentioned study, official approval of this study by our committee was not required. Medisch-ethische toetsingscommissie (METC) azM/UMI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study have been deposited at https://github.com/BiGCAT-UM/IMD-PUPY . https://github.com/BiGCAT-UM/IMD-PUPY https://doi.org/10.5281/ZENODO.5632921